At Investor Conferences

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1604 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Yukin Therapeutics–Advent France Biotechnology: investment, 201906 financing round totalling €3.3m incl founding + co-lead investor Advent France Bio 2019-06-04
Yukin Therapeutics–Medicxi: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi 2019-06-04
Yukin Therapeutics–NewCap: public relations, 201906 service existent by NewCap 2019-06-04
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Domain Therapeutics–BPCE: investment, 201905 investment €3.5m from existing investor Seventure Partners 2019-05-28
Sensorion–Institut Pasteur: gene therapy, 201905– collab framework agreem incl license options for gene therapies for ear diseases 2019-05-27
DNA Script–France (govt): investment, 201905 financing round Series B totalling $38.5m incl new investor Bpifrance Large Venture fund 2019-05-16
DNA Script–Idinvest Partners: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Idinvest Partners 2019-05-16
DNA Script–Illumina: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Illumina Ventures 2019-05-16
DNA Script–Kurma: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Kurma Partners 2019-05-16
DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP 2019-05-16
DNA Script–Merck (DE): investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor M Ventures 2019-05-16
DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP 2019-05-16
DNA Script–Sofinnova: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Sofinnova Partners 2019-05-16
TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA 2019-05-13
TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al 2019-05-13
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures 2019-04-30
Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners 2019-04-30
Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance 2019-04-30
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen 2019-04-29
Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast 2019-04-19
Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group 2019-04-09
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 2019-03-27
Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF 2019-03-21
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects 2019-03-14
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research 2019-03-01
Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market 2019-02-27
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED 2019-02-13
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners 2019-02-01
Axial Biotherapeutics–SEVERAL: investment, 201902 financing round Series B $25m incl Seventure Partners 2019-02-01
Pharnext–CB Lux: investment, 201901 private placement €15m with 1.02m new shares at €14.7/share to CB Lux raising share from 21.12% to 27.79% 2019-01-23
ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models 2019-01-17
ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging 2019-01-17
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies 2019-01-15
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
MycoTechnology–SEVERAL: investment, 201901 financing round Series C $30m 2019-01-01
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing 2018-12-17
Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–NewCap: public relations, 201812 service existent by NewCap 2018-12-14
Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m 2018-12-14
Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top